SCHEMBL6424210

SCHEMBL6424210

O=C(Nc1ccc(NC(=O)c2cccc(Cl)c2)c2c1C(=O)c1ccccc1C2=O)c1cccc(Cl)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
MMP14 P50281 1/20 0.60
CYP1A2 P05177 1/20 0.57
TSHR P16473 1/20 0.57
KCNMA1 Q12791 1/20 0.57
MAPT P10636 2/20 0.56
KCNK3 O14649 2/20 0.55
KCNK9 Q9NPC2 2/20 0.55
HSP90AA1 P07900 2/20 0.54
HSP90AB1 P08238 2/20 0.54
SERPINE1 P05121 1/20 0.53
AKR1C4 P17516 1/20 0.52
AKR1C3 P42330 1/20 0.52
AKR1C2 P52895 1/20 0.52
AKR1C1 Q04828 1/20 0.52
CASP3 P42574 1/20 0.52
RXFP1 Q9HBX9 1/20 0.51
POLB P06746 1/20 0.50
NPC1 O15118 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10726036 0.92 MEN1 (0.74) MEN1KMT2AMMP14CYP1A2TSHR
SCHEMBL11413623 0.90 KCNMA1 (0.58) MEN1KMT2AKCNMA1KCNK3KCNK9
SCHEMBL13656878 0.87 MEN1 (0.51) MEN1KMT2AMMP14CYP1A2TSHR
SCHEMBL11299034 0.86 MEN1 (0.56) MEN1KMT2AMMP14CYP1A2TSHR
SCHEMBL11299151 0.84 MEN1 (0.54) MEN1KMT2AMMP14CYP1A2TSHR
SCHEMBL6417715 0.84 KMT2A (0.69) MEN1KMT2AMMP14CYP1A2TSHR
SCHEMBL6419867 0.83 MEN1 (0.82) MEN1KMT2AMMP14CYP1A2TSHR
SCHEMBL30544874 0.83 MEN1 (0.82) MEN1KMT2AMMP14CYP1A2TSHR
SCHEMBL6421461 0.83 MEN1 (0.60) MEN1KMT2AMMP14CYP1A2TSHR
SCHEMBL10723741 0.83 MEN1 (0.54) MEN1KMT2AMMP14CYP1A2KCNMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009924-A1 Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives HUANG HSU-SHAN (TW) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009924-A1 Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives NFE2L2, NR2F2, TFAM MEN1 4402/4885KMT2A 1696/4885MMP14 2848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.